Chester County News and Community Website
BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced recent approval for additional European clinical trial sites for the ongoing Phase 3 study of buntanetap for the treatment of Parkinson’s disease (“PD”).
Annovis Bio Announces Approval for European Union Clinical Trial Sites for the Phase 3 Study of Buntanetap Read More
HORSHAM, PA — Clinical ink, a global life science technology company, has partnered with a leading biopharmaceutical organization focused on Parkinson’s Disease research to deploy remote technology that captures study participants’ symptoms …
Clinical ink Selected for Global Late Phase Parkinson’s Disease Programs Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that the first patient in a trial to test the effectiveness of buntanetap on early Parkinson’s Disease was recently dosed.
Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) recently announced second quarter financial results for the quarter ended June 30, 2022, and reviewed recent accomplishments.
Annovis Bio Expands Intellectual Property Portfolio Around PD Drug Candidate Read More BERWYN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that the Company recently received notice from the FDA that the Phase 3 clinical study in early Parkinson’s patients may proceed. The …
Annovis Bio Announces Positive FDA Notice For Buntanetap Phase 3 Clinical Trial In Parkinson’s Disease Read More
PAOLI, PA — Daylesford Crossing, a SageLife senior living community in Paoli, Pennsylvania, has launched a new program to care for individuals with Parkinson’s Disease and other movement disorders.
New Program at Daylesford Crossing to Care for Individuals with Parkinson’s and Movement Disorders Read More
Parkinson’s Disease (PD) impacts up to one in 15 individuals in the United States. People with PD often experience symptoms that impact their movement, like tremors, shuffling feet while walking, …
For Parkinson’s Disease Patients, Effective Implantable Therapy Can Now Last Up to 15 Years Read More